Créteil Hospital
6
1
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection
Role: collaborator
The Role of Inflammatory Processes in Development and Treatment of Depression
Role: collaborator
Diagnostic Performance Comparison Between Procalcitonin-based vs. ANAES-based Guidelines
Role: collaborator
Predictors of Suicidal Behavior in Depression
Role: collaborator
Molecular Genetics of Suicidal Behavior
Role: collaborator
Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient
Role: collaborator
All 6 trials loaded